BRAF inhibitors and their immunological effects in malignant melanoma.

Rebecca AdamsJack E M CoumbeBen G T CoumbeJennifer ThomasZena WillsmoreMarija DimitrievskaMonica Yasuzawa-ParkerMaximilian HoyleSuhaylah IngarJenny L C GehAlastair D MacKenzie-RossCiaran HealySophie PapaKatie E LacySophia N Karagiannis

Published in: Expert review of clinical immunology (2022)

MAPKi in combination or in sequence with established treatments such as checkpoint inhibitors, anti-angiogenic agents, or new therapies such as adoptive cell therapies, may augment their immunological effects, reverse tumor-associated immune suppression, and offer the prospect of longer-lived clinical responses. Refining therapeutic tools at our disposal and embracing 'old friends' in the melanoma treatment arsenal, alongside new target identification, may improve the chances of therapeutic success.

Keyphrases

cell therapy
dna damage
risk assessment
current status
amino acid
bioinformatics analysis
skin cancer